Finch Therapeutics(FNCH)
BOSTON, MABiotechnology
Focus: Finch Therapeutics is a Boston-based public biotech focused on microbiological therapy, developing live biotherapeutic products (LBPs) derived from fecal microbiota for infectious and neurological indications. The company is in early commercialization stage with minimal revenue generation.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Total Funding
$90M
Open Jobs
11+11 this month
Growing — net +11 jobs in 30d
12 jobs added vs 1 removed. Steady team buildout.
Should You Work at Finch Therapeutics?
AI assessmentFinch represents a high-risk, early-stage opportunity suitable only for risk-tolerant professionals seeking frontier science exposure; viability depends critically on Phase 3 CP101 success and near-term capital access.
Why Work Here
- Pioneer in live biotherapeutic modality with multiple programs across infectious disease and neurology addressing underserved indications like C. difficile and autism spectrum disorder.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$861K
Pipeline & Clinical Trials
Physical examination
Anal Intraepithelial NeoplasiaClinical Trials (1)
NCT05858021COrSIcA: Disease Measurement
N/AHelp build intelligence for Finch Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.